Nuclear Medicine Market by Product (Diagnostic Medicine, Therapeutic Medicine); by Applications (Diagnostic Application, Therapeutic Application); by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, Rest of the World) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018-2026

Report ID :AMI-32 | Category : Healthcare | Published Date :April, 2018 | Pages : 234 | Format :PDF
Buy Now!

Industry Trends

Nuclear medicines are radioactive materials called radiotracers that are injected into the bloodstream, inhaled or swallowed. It is used in diagnosis of various diseases. The radiotracer travels through the area to be examined and the energy released from these radiotracers in the form of gamma rays are detected by a special camera and a computer.  Nuclear medicine imaging helps to collect unique information that often cannot be obtained using other imaging techniques and offers the scope to identify disease in its earliest stages. The nuclear medicine market, in terms of revenue, was valued at US$ 4.62 Bn in 2016 and is expected to reach US$ 6.81 Bn by 2021.

Nuclear Medicine Market, By Product Type, 2018-2026 (US$ Billion)

Nuclear Medicine Market

Nuclear Medicine Market, by Product Type

Global market based on the product type is classified as diagnostic medicine and therapeutic medicine. In the diagnosis, there are two types of imaging techniques which includes, single-photon emission computed tomography (SPECT) and positron emission tomography (PET). These techniques are very helpful in diagnosis of gall bladder disease, thyroid disease, cancer, Alzheimer's disease, heart conditions and brain conditions. The diagnostic medicine held the largest share in global nuclear medicine market and is also anticipated to be the fastest growing market in terms of the CAGR. The growing importance of diagnosis of fatal diseases among people, has driven the diagnostic medicine segment.

Nuclear Medicine Market, by Region

In the global market, North America is expected to be the leading market during the forecast period. The United States has shown substantial growth in the North America region. This growth is mainly attributed to the advancement in technology such as the development of molecular imaging based on the tracer principle, the introduction of new radiopharmaceuticals for diagnosis and therapy and hybrid imaging. The Europe and Asia Pacific areas account for noteworthy shares in the nuclear medicine market.

Competitive Market Share

The report provides both, qualitative and quantitative research of the market, as well as it helps to gain important insights of current and future market and trending technologies adopted by the key players. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers and acquisitions(M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their manufacturing base, competitors, product type, application and specification, pricing, and gross margin.

Some of the key participants of global nuclear medicine market are Cardinal Health, Inc., Medtronic, Minimally Invasive Therapies, Ion Beam Applications S.A (IBA Worldwide), Lantheus Medical Imaging Inc., General Electric Company, Bracco Imaging S.p.A, Bayer AG, Advanced Medical Isotope Corporation, Alliance Medical Limited, Alseres Pharmaceuticals, Inc., Avid Radiopharmaceuticals, Inc., Actinium Pharmaceuticals, Inc., Immunomedics, Inc., Jubilant Pharma LLC, Mallinckrodt Pharmaceuticals, Medi-Radiopharma Co., Ltd., Peregrine Pharmaceuticals, Inc. and Positron Corporation, Nordion (Canada) Inc. amongst others.

Nuclear Medicine Industry Background

Nuclear Medicine MarketNuclear Medicine Market

1.    Introduction

1.1.   Market Scope

1.2.   Market Segmentation

1.3.   Methodology

1.4.   Assumptions

2.    Nuclear Medicine Market Snapshot

3.    Executive Summary: Nuclear Medicine Market

4.    Qualitative Analysis: Nuclear Medicine Market

4.1.   Introduction

4.1.1.   Product Definition

4.1.2.   Industry Development

4.2.   Market Dynamics

4.2.1.   Drivers

4.2.2.   Restraints

4.2.3.   Opportunities

4.3.   Trends in Market

5.    Global Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026

5.1.   Overview

5.1.1.   Global Market Revenue (US$ Mn) and Forecasts

5.2.   Global Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

5.2.1.   Diagnostic Medicine (Definition, Market Penetration, Market Revenue Expected to Increase by 2026, Compound Annual Growth Rate (CAGR) and information on SPECT Radiopharmaceutical, PET Radiopharmaceutical)

5.2.1.1.    SPECT Radiopharmaceutical

5.2.1.2.    PET Radiopharmaceutical

5.2.2.   Therapeutic Medicine (Definition, Market Penetration, Market Revenue Expected to Increase by 2026, Compound Annual Growth Rate (CAGR) and information on Beta Emitters, Alpha Emitters, Brachytherapy Isotopes)

5.2.2.1.    Beta Emitters

5.2.2.2.    Alpha Emitters

5.2.2.3.    Brachytherapy Isotopes

5.3.   Key Segment for Channeling Investments

5.3.1.   By Product

6.    Global Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026

6.1.   Overview

6.2.   Global Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

6.2.1.   Diagnostic Application (Definition, Market Penetration, Market Revenue Expected to Increase by 2026, Compound Annual Growth Rate (CAGR) and information on Oncology, Cardiology, Neurology, Others)

6.2.1.1.    Oncology

6.2.1.2.    Cardiology

6.2.1.3.    Neurology

6.2.1.4.    Others

6.2.2.   Therapeutic Application (Definition, Market Penetration, Market Revenue Expected to Increase by 2026, Compound Annual Growth Rate (CAGR) and information on Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)

6.2.2.1.    Thyroid

6.2.2.2.    Bone Metastasis

6.2.2.3.    Lymphoma

6.2.2.4.    Endocrine Tumors

6.2.2.5.    Others

6.3.   Key Segment for Channeling Investments

6.3.1.   By Applications

7.    North America Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026

7.1.   Overview

7.1.1.   North America Market Revenue (US$ Mn)

7.2.   North America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

7.2.1.   Diagnostic Medicine

7.2.1.1.    SPECT Radiopharmaceutical

7.2.1.2.    PET Radiopharmaceutical

7.2.2.   Therapeutic Medicine

7.2.2.1.    Beta Emitters

7.2.2.2.    Alpha Emitters

7.2.2.3.    Brachytherapy Isotopes

7.3.   North America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

7.3.1.   Diagnostic Application

7.3.1.1.    Oncology

7.3.1.2.    Cardiology

7.3.1.3.    Neurology

7.3.1.4.    Others

7.3.2.   Therapeutic Application

7.3.2.1.    Thyroid

7.3.2.2.    Bone Metastasis

7.3.2.3.    Lymphoma

7.3.2.4.    Endocrine Tumors

7.3.2.5.    Others

7.4.   North America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Country

7.4.1.   U.S.

7.4.1.1.    U.S. Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

7.4.1.1.1.    Diagnostic Medicine

7.4.1.1.1.1.  SPECT Radiopharmaceutical

7.4.1.1.1.2.  PET Radiopharmaceutical

7.4.1.1.2.    Therapeutic Medicine

7.4.1.1.2.1.  Beta Emitters

7.4.1.1.2.2.  Alpha Emitters

7.4.1.1.2.3.  Brachytherapy Isotopes

7.4.1.2.    U.S. Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

7.4.1.2.1.    Diagnostic Application

7.4.1.2.1.1.  Oncology

7.4.1.2.1.2.  Cardiology

7.4.1.2.1.3.  Neurology

7.4.1.2.1.4.  Others

7.4.1.2.2.    Therapeutic Application

7.4.1.2.2.1.  Thyroid

7.4.1.2.2.2.  Bone Metastasis

7.4.1.2.2.3.  Lymphoma

7.4.1.2.2.4.  Endocrine Tumors

7.4.1.2.2.5.  Others

7.4.2.   Rest of North America

7.4.2.1.    Rest of North America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

7.4.2.1.1.    Diagnostic Medicine

7.4.2.1.1.1.  SPECT Radiopharmaceutical

7.4.2.1.1.2.  PET Radiopharmaceutical

7.4.2.1.2.    Therapeutic Medicine

7.4.2.1.2.1.  Beta Emitters

7.4.2.1.2.2.  Alpha Emitters

7.4.2.1.2.3.  Brachytherapy Isotopes

7.4.2.2.    Rest of North America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

7.4.2.2.1.    Diagnostic Application

7.4.2.2.1.1.  Oncology

7.4.2.2.1.2.  Cardiology

7.4.2.2.1.3.  Neurology

7.4.2.2.1.4.  Others

7.4.2.2.2.    Therapeutic Application

7.4.2.2.2.1.  Thyroid

7.4.2.2.2.2.  Bone Metastasis

7.4.2.2.2.3.  Lymphoma

7.4.2.2.2.4.  Endocrine Tumors

7.4.2.2.2.5.  Others

7.5.   Key Segment for Channeling Investments

7.5.1.   By Country

7.5.2.   By Product

7.5.3.   By Applications

8.    Europe Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026

8.1.   Overview

8.1.1.   Europe Market Revenue (US$ Mn)

8.2.   Europe Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

8.2.1.   Diagnostic Medicine

8.2.1.1.    SPECT Radiopharmaceutical

8.2.1.2.    PET Radiopharmaceutical

8.2.2.   Therapeutic Medicine

8.2.2.1.    Beta Emitters

8.2.2.2.    Alpha Emitters

8.2.2.3.    Brachytherapy Isotopes

8.3.   Europe Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

8.3.1.   Diagnostic Application

8.3.1.1.    Oncology

8.3.1.2.    Cardiology

8.3.1.3.    Neurology

8.3.1.4.    Others

8.3.2.   Therapeutic Application

8.3.2.1.    Thyroid

8.3.2.2.    Bone Metastasis

8.3.2.3.    Lymphoma

8.3.2.4.    Endocrine Tumors

8.3.2.5.    Others

8.4.   Europe Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Country

8.4.1.   France

8.4.1.1.    France Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

8.4.1.1.1.    Diagnostic Medicine

8.4.1.1.1.1.  SPECT Radiopharmaceutical

8.4.1.1.1.2.  PET Radiopharmaceutical

8.4.1.1.2.    Therapeutic Medicine

8.4.1.1.2.1.  Beta Emitters

8.4.1.1.2.2.  Alpha Emitters

8.4.1.1.2.3.  Brachytherapy Isotopes

8.4.1.2.    France Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.1.2.1.    Diagnostic Application

8.4.1.2.1.1.  Oncology

8.4.1.2.1.2.  Cardiology

8.4.1.2.1.3.  Neurology

8.4.1.2.1.4.  Others

8.4.1.2.2.    Therapeutic Application

8.4.1.2.2.1.  Thyroid

8.4.1.2.2.2.  Bone Metastasis

8.4.1.2.2.3.  Lymphoma

8.4.1.2.2.4.  Endocrine Tumors

8.4.1.2.2.5.  Others

8.4.2.   The UK

8.4.2.1.    The UK Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

8.4.2.1.1.    Diagnostic Medicine

8.4.2.1.1.1.  SPECT Radiopharmaceutical

8.4.2.1.1.2.  PET Radiopharmaceutical

8.4.2.1.2.    Therapeutic Medicine

8.4.2.1.2.1.  Beta Emitters

8.4.2.1.2.2.  Alpha Emitters

8.4.2.1.2.3.  Brachytherapy Isotopes

8.4.2.2.    The UK Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.2.2.1.    Diagnostic Application

8.4.2.2.1.1.  Oncology

8.4.2.2.1.2.  Cardiology

8.4.2.2.1.3.  Neurology

8.4.2.2.1.4.  Others

8.4.2.2.2.    Therapeutic Application

8.4.2.2.2.1.  Thyroid

8.4.2.2.2.2.  Bone Metastasis

8.4.2.2.2.3.  Lymphoma

8.4.2.2.2.4.  Endocrine Tumors

8.4.2.2.2.5.  Others

8.4.3.   Spain

8.4.3.1.    Spain Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

8.4.3.1.1.    Diagnostic Medicine

8.4.3.1.1.1.  SPECT Radiopharmaceutical

8.4.3.1.1.2.  PET Radiopharmaceutical

8.4.3.1.2.    Therapeutic Medicine

8.4.3.1.2.1.  Beta Emitters

8.4.3.1.2.2.  Alpha Emitters

8.4.3.1.2.3.  Brachytherapy Isotopes

8.4.3.2.    Spain Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.3.2.1.    Diagnostic Application

8.4.3.2.1.1.  Oncology

8.4.3.2.1.2.  Cardiology

8.4.3.2.1.3.  Neurology

8.4.3.2.1.4.  Others

8.4.3.2.2.    Therapeutic Application

8.4.3.2.2.1.  Thyroid

8.4.3.2.2.2.  Bone Metastasis

8.4.3.2.2.3.  Lymphoma

8.4.3.2.2.4.  Endocrine Tumors

8.4.3.2.2.5.  Others

8.4.4.   Germany

8.4.4.1.    Germany Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

8.4.4.1.1.    Diagnostic Medicine

8.4.4.1.1.1.  SPECT Radiopharmaceutical

8.4.4.1.1.2.  PET Radiopharmaceutical

8.4.4.1.2.    Therapeutic Medicine

8.4.4.1.2.1.  Beta Emitters

8.4.4.1.2.2.  Alpha Emitters

8.4.4.1.2.3.  Brachytherapy Isotopes

8.4.4.2.    Germany Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.4.2.1.    Diagnostic Application

8.4.4.2.1.1.  Oncology

8.4.4.2.1.2.  Cardiology

8.4.4.2.1.3.  Neurology

8.4.4.2.1.4.  Others

8.4.4.2.2.    Therapeutic Application

8.4.4.2.2.1.  Thyroid

8.4.4.2.2.2.  Bone Metastasis

8.4.4.2.2.3.  Lymphoma

8.4.4.2.2.4.  Endocrine Tumors

8.4.4.2.2.5.  Others

8.4.5.   Italy

8.4.5.1.    Italy Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

8.4.5.1.1.    Diagnostic Medicine

8.4.5.1.1.1.  SPECT Radiopharmaceutical

8.4.5.1.1.2.  PET Radiopharmaceutical

8.4.5.1.2.    Therapeutic Medicine

8.4.5.1.2.1.  Beta Emitters

8.4.5.1.2.2.  Alpha Emitters

8.4.5.1.2.3.  Brachytherapy Isotopes

8.4.5.2.    Italy Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.5.2.1.    Diagnostic Application

8.4.5.2.1.1.  Oncology

8.4.5.2.1.2.  Cardiology

8.4.5.2.1.3.  Neurology

8.4.5.2.1.4.  Others

8.4.5.2.2.    Therapeutic Application

8.4.5.2.2.1.  Thyroid

8.4.5.2.2.2.  Bone Metastasis

8.4.5.2.2.3.  Lymphoma

8.4.5.2.2.4.  Endocrine Tumors

8.4.5.2.2.5.  Others

8.4.6.   Rest of Europe

8.4.6.1.    Rest of Europe Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

8.4.6.1.1.    Diagnostic Medicine

8.4.6.1.1.1.  SPECT Radiopharmaceutical

8.4.6.1.1.2.  PET Radiopharmaceutical

8.4.6.1.2.    Therapeutic Medicine

8.4.6.1.2.1.  Beta Emitters

8.4.6.1.2.2.  Alpha Emitters

8.4.6.1.2.3.  Brachytherapy Isotopes

8.4.6.2.    Rest of Europe Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.6.2.1.    Diagnostic Application

8.4.6.2.1.1.  Oncology

8.4.6.2.1.2.  Cardiology

8.4.6.2.1.3.  Neurology

8.4.6.2.1.4.  Others

8.4.6.2.2.    Therapeutic Application

8.4.6.2.2.1.  Thyroid

8.4.6.2.2.2.  Bone Metastasis

8.4.6.2.2.3.  Lymphoma

8.4.6.2.2.4.  Endocrine Tumors

8.4.6.2.2.5.  Others

8.5.   Key Segment for Channeling Investments

8.5.1.   By Country

8.5.2.   By Product

8.5.3.   By Applications

9.    Asia Pacific Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026

9.1.   Overview

9.1.1.   Asia Pacific Market Revenue (US$ Mn)

9.2.   Asia Pacific Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

9.2.1.   Diagnostic Medicine

9.2.1.1.    SPECT Radiopharmaceutical

9.2.1.2.    PET Radiopharmaceutical

9.2.2.   Therapeutic Medicine

9.2.2.1.    Beta Emitters

9.2.2.2.    Alpha Emitters

9.2.2.3.    Brachytherapy Isotopes

9.3.   Asia Pacific Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

9.3.1.   Diagnostic Application

9.3.1.1.    Oncology

9.3.1.2.    Cardiology

9.3.1.3.    Neurology

9.3.1.4.    Others

9.3.2.   Therapeutic Application

9.3.2.1.    Thyroid

9.3.2.2.    Bone Metastasis

9.3.2.3.    Lymphoma

9.3.2.4.    Endocrine Tumors

9.3.2.5.    Others

9.4.   Asia Pacific Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Country

9.4.1.   China

9.4.1.1.    China Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

9.4.1.1.1.    Diagnostic Medicine

9.4.1.1.1.1.  SPECT Radiopharmaceutical

9.4.1.1.1.2.  PET Radiopharmaceutical

9.4.1.1.2.    Therapeutic Medicine

9.4.1.1.2.1.  Beta Emitters

9.4.1.1.2.2.  Alpha Emitters

9.4.1.1.2.3.  Brachytherapy Isotopes

9.4.1.2.    China Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

9.4.1.2.1.    Diagnostic Application

9.4.1.2.1.1.  Oncology

9.4.1.2.1.2.  Cardiology

9.4.1.2.1.3.  Neurology

9.4.1.2.1.4.  Others

9.4.1.2.2.    Therapeutic Application

9.4.1.2.2.1.  Thyroid

9.4.1.2.2.2.  Bone Metastasis

9.4.1.2.2.3.  Lymphoma

9.4.1.2.2.4.  Endocrine Tumors

9.4.1.2.2.5.  Others

9.4.2.   Japan

9.4.2.1.    Japan Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

9.4.2.1.1.    Diagnostic Medicine

9.4.2.1.1.1.  SPECT Radiopharmaceutical

9.4.2.1.1.2.  PET Radiopharmaceutical

9.4.2.1.2.    Therapeutic Medicine

9.4.2.1.2.1.  Beta Emitters

9.4.2.1.2.2.  Alpha Emitters

9.4.2.1.2.3.  Brachytherapy Isotopes

9.4.2.2.    Japan Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

9.4.2.2.1.    Diagnostic Application

9.4.2.2.1.1.  Oncology

9.4.2.2.1.2.  Cardiology

9.4.2.2.1.3.  Neurology

9.4.2.2.1.4.  Others

9.4.2.2.2.    Therapeutic Application

9.4.2.2.2.1.  Thyroid

9.4.2.2.2.2.  Bone Metastasis

9.4.2.2.2.3.  Lymphoma

9.4.2.2.2.4.  Endocrine Tumors

9.4.2.2.2.5.  Others

9.4.3.   India

9.4.3.1.    India Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

9.4.3.1.1.    Diagnostic Medicine

9.4.3.1.1.1.  SPECT Radiopharmaceutical

9.4.3.1.1.2.  PET Radiopharmaceutical

9.4.3.1.2.    Therapeutic Medicine

9.4.3.1.2.1.  Beta Emitters

9.4.3.1.2.2.  Alpha Emitters

9.4.3.1.2.3.  Brachytherapy Isotopes

9.4.3.2.    India Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

9.4.3.2.1.    Diagnostic Application

9.4.3.2.1.1.  Oncology

9.4.3.2.1.2.  Cardiology

9.4.3.2.1.3.  Neurology

9.4.3.2.1.4.  Others

9.4.3.2.2.    Therapeutic Application

9.4.3.2.2.1.  Thyroid

9.4.3.2.2.2.  Bone Metastasis

9.4.3.2.2.3.  Lymphoma

9.4.3.2.2.4.  Endocrine Tumors

9.4.3.2.2.5.  Others

9.4.4.   Southeast Asia

9.4.4.1.    Southeast Asia Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

9.4.4.1.1.    Diagnostic Medicine

9.4.4.1.1.1.  SPECT Radiopharmaceutical

9.4.4.1.1.2.  PET Radiopharmaceutical

9.4.4.1.2.    Therapeutic Medicine

9.4.4.1.2.1.  Beta Emitters

9.4.4.1.2.2.  Alpha Emitters

9.4.4.1.2.3.  Brachytherapy Isotopes

9.4.4.2.    Southeast Asia Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

9.4.4.2.1.    Diagnostic Application

9.4.4.2.1.1.  Oncology

9.4.4.2.1.2.  Cardiology

9.4.4.2.1.3.  Neurology

9.4.4.2.1.4.  Others

9.4.4.2.2.    Therapeutic Application

9.4.4.2.2.1.  Thyroid

9.4.4.2.2.2.  Bone Metastasis

9.4.4.2.2.3.  Lymphoma

9.4.4.2.2.4.  Endocrine Tumors

9.4.4.2.2.5.  Others

9.4.5.   Rest of Asia Pacific

9.4.5.1.    Rest of Asia Pacific Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

9.4.5.1.1.    Diagnostic Medicine

9.4.5.1.1.1.  SPECT Radiopharmaceutical

9.4.5.1.1.2.  PET Radiopharmaceutical

9.4.5.1.2.    Therapeutic Medicine

9.4.5.1.2.1.  Beta Emitters

9.4.5.1.2.2.  Alpha Emitters

9.4.5.1.2.3.  Brachytherapy Isotopes

9.4.5.2.    Rest of Asia Pacific Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

9.4.5.2.1.    Diagnostic Application

9.4.5.2.1.1.  Oncology

9.4.5.2.1.2.  Cardiology

9.4.5.2.1.3.  Neurology

9.4.5.2.1.4.  Others

9.4.5.2.2.    Therapeutic Application

9.4.5.2.2.1.  Thyroid

9.4.5.2.2.2.  Bone Metastasis

9.4.5.2.2.3.  Lymphoma

9.4.5.2.2.4.  Endocrine Tumors

9.4.5.2.2.5.  Others

9.5.   Key Segment for Channeling Investments

9.5.1.   By Country

9.5.2.   By Product

9.5.3.   By Applications

10. Middle East and Africa Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026

10.1. Overview

10.1.1. Middle East and Africa Market Revenue (US$ Mn)

10.2. Middle East and Africa Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

10.2.1. Diagnostic Medicine

10.2.1.1.  SPECT Radiopharmaceutical

10.2.1.2.  PET Radiopharmaceutical

10.2.2. Therapeutic Medicine

10.2.2.1.  Beta Emitters

10.2.2.2.  Alpha Emitters

10.2.2.3.  Brachytherapy Isotopes

10.3. Middle East and Africa Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

10.3.1. Diagnostic Application

10.3.1.1.  Oncology

10.3.1.2.  Cardiology

10.3.1.3.  Neurology

10.3.1.4.  Others

10.3.2. Therapeutic Application

10.3.2.1.  Thyroid

10.3.2.2.  Bone Metastasis

10.3.2.3.  Lymphoma

10.3.2.4.  Endocrine Tumors

10.3.2.5.  Others

10.4. Middle East and Africa Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. GCC Countries

10.4.1.1.  GCC Countries Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

10.4.1.1.1.  Diagnostic Medicine

10.4.1.1.1.1.  SPECT Radiopharmaceutical

10.4.1.1.1.2.  PET Radiopharmaceutical

10.4.1.1.2.  Therapeutic Medicine

10.4.1.1.2.1.  Beta Emitters

10.4.1.1.2.2.  Alpha Emitters

10.4.1.1.2.3.  Brachytherapy Isotopes

10.4.1.2.  GCC Countries Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

10.4.1.2.1.  Diagnostic Application

10.4.1.2.1.1.  Oncology

10.4.1.2.1.2.  Cardiology

10.4.1.2.1.3.  Neurology

10.4.1.2.1.4.  Others

10.4.1.2.2.  Therapeutic Application

10.4.1.2.2.1.  Thyroid

10.4.1.2.2.2.  Bone Metastasis

10.4.1.2.2.3.  Lymphoma

10.4.1.2.2.4.  Endocrine Tumors

10.4.1.2.2.5.  Others

10.4.2. Southern Africa

10.4.2.1.  Southern Africa Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

10.4.2.1.1.  Diagnostic Medicine

10.4.2.1.1.1.  SPECT Radiopharmaceutical

10.4.2.1.1.2.  PET Radiopharmaceutical

10.4.2.1.2.  Therapeutic Medicine

10.4.2.1.2.1.  Beta Emitters

10.4.2.1.2.2.  Alpha Emitters

10.4.2.1.2.3.  Brachytherapy Isotopes

10.4.2.2.  Southern Africa Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

10.4.2.2.1.  Diagnostic Application

10.4.2.2.1.1.  Oncology

10.4.2.2.1.2.  Cardiology

10.4.2.2.1.3.  Neurology

10.4.2.2.1.4.  Others

10.4.2.2.2.  Therapeutic Application

10.4.2.2.2.1.  Thyroid

10.4.2.2.2.2.  Bone Metastasis

10.4.2.2.2.3.  Lymphoma

10.4.2.2.2.4.  Endocrine Tumors

10.4.2.2.2.5.  Others

10.4.3. Rest of MEA

10.4.3.1.  Rest of MEA Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

10.4.3.1.1.  Diagnostic Medicine

10.4.3.1.1.1.  SPECT Radiopharmaceutical

10.4.3.1.1.2.  PET Radiopharmaceutical

10.4.3.1.2.  Therapeutic Medicine

10.4.3.1.2.1.  Beta Emitters

10.4.3.1.2.2.  Alpha Emitters

10.4.3.1.2.3.  Brachytherapy Isotopes

10.4.3.2.  Rest of MEA Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

10.4.3.2.1.  Diagnostic Application

10.4.3.2.1.1.  Oncology

10.4.3.2.1.2.  Cardiology

10.4.3.2.1.3.  Neurology

10.4.3.2.1.4.  Others

10.4.3.2.2.  Therapeutic Application

10.4.3.2.2.1.  Thyroid

10.4.3.2.2.2.  Bone Metastasis

10.4.3.2.2.3.  Lymphoma

10.4.3.2.2.4.  Endocrine Tumors

10.4.3.2.2.5.  Others

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Product

10.5.3. By Applications

11. Latin America Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026

11.1. Overview

11.1.1. Latin America Market Revenue (US$ Mn)

11.2. Latin America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

11.2.1. Diagnostic Medicine

11.2.1.1.  SPECT Radiopharmaceutical

11.2.1.2.  PET Radiopharmaceutical

11.2.2. Therapeutic Medicine

11.2.2.1.  Beta Emitters

11.2.2.2.  Alpha Emitters

11.2.2.3.  Brachytherapy Isotopes

11.3. Latin America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

11.3.1. Diagnostic Application

11.3.1.1.  Oncology

11.3.1.2.  Cardiology

11.3.1.3.  Neurology

11.3.1.4.  Others

11.3.2. Therapeutic Application

11.3.2.1.  Thyroid

11.3.2.2.  Bone Metastasis

11.3.2.3.  Lymphoma

11.3.2.4.  Endocrine Tumors

11.3.2.5.  Others

11.4. Latin America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. Brazil

11.4.1.1.  Brazil Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

11.4.1.1.1.  Diagnostic Medicine

11.4.1.1.1.1.  SPECT Radiopharmaceutical

11.4.1.1.1.2.  PET Radiopharmaceutical

11.4.1.1.2.  Therapeutic Medicine

11.4.1.1.2.1.  Beta Emitters

11.4.1.1.2.2.  Alpha Emitters

11.4.1.1.2.3.  Brachytherapy Isotopes

11.4.1.2.  Brazil Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

11.4.1.2.1.  Diagnostic Application

11.4.1.2.1.1.  Oncology

11.4.1.2.1.2.  Cardiology

11.4.1.2.1.3.  Neurology

11.4.1.2.1.4.  Others

11.4.1.2.2.  Therapeutic Application

11.4.1.2.2.1.  Thyroid

11.4.1.2.2.2.  Bone Metastasis

11.4.1.2.2.3.  Lymphoma

11.4.1.2.2.4.  Endocrine Tumors

11.4.1.2.2.5.  Others

11.4.2. Rest of Latin America

11.4.2.1.  Rest of Latin America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product

11.4.2.1.1.  Diagnostic Medicine

11.4.2.1.1.1.  SPECT Radiopharmaceutical

11.4.2.1.1.2.  PET Radiopharmaceutical

11.4.2.1.2.  Therapeutic Medicine

11.4.2.1.2.1.  Beta Emitters

11.4.2.1.2.2.  Alpha Emitters

11.4.2.1.2.3.  Brachytherapy Isotopes

11.4.2.2.  Rest of Latin America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications

11.4.2.2.1.  Diagnostic Application

11.4.2.2.1.1.  Oncology

11.4.2.2.1.2.  Cardiology

11.4.2.2.1.3.  Neurology

11.4.2.2.1.4.  Others

11.4.2.2.2.  Therapeutic Application

11.4.2.2.2.1.  Thyroid

11.4.2.2.2.2.  Bone Metastasis

11.4.2.2.2.3.  Lymphoma

11.4.2.2.2.4.  Endocrine Tumors

11.4.2.2.2.5.  Others

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Product

11.5.3. By Applications

12. Competitive Benchmarking

12.1. Player Positioning Analysis

12.2. Global Presence and Growth Strategies

13. Player Profiles

13.1. Cardinal Health, Inc.

13.1.1. Company Details

13.1.2. Company Overview

13.1.3. Product Offerings

13.1.4. Key Developments

13.1.5. Financial Analysis

13.1.6. SWOT Analysis

13.1.7. Business Strategies

13.2. Medtronic

13.2.1. Company Details

13.2.2. Company Overview

13.2.3. Product Offerings

13.2.4. Key Developments

13.2.5. Financial Analysis

13.2.6. SWOT Analysis

13.2.7. Business Strategies

13.3. Minimally Invasive Therapies

13.3.1. Company Details

13.3.2. Company Overview

13.3.3. Product Offerings

13.3.4. Key Developments

13.3.5. Financial Analysis

13.3.6. SWOT Analysis

13.3.7. Business Strategies

13.4. Ion Beam Applications S.A (IBA Worldwide)

13.4.1. Company Details

13.4.2. Company Overview

13.4.3. Product Offerings

13.4.4. Key Developments

13.4.5. Financial Analysis

13.4.6. SWOT Analysis

13.4.7. Business Strategies

13.5. Lantheus Medical Imaging Inc.

13.5.1. Company Details

13.5.2. Company Overview

13.5.3. Product Offerings

13.5.4. Key Developments

13.5.5. Financial Analysis

13.5.6. SWOT Analysis

13.5.7. Business Strategies

13.6. General Electric Company

13.6.1. Company Details

13.6.2. Company Overview

13.6.3. Product Offerings

13.6.4. Key Developments

13.6.5. Financial Analysis

13.6.6. SWOT Analysis

13.6.7. Business Strategies

13.7. Bracco Imaging S.p.A

13.7.1. Company Details

13.7.2. Company Overview

13.7.3. Product Offerings

13.7.4. Key Developments

13.7.5. Financial Analysis

13.7.6. SWOT Analysis

13.7.7. Business Strategies

13.8. Bayer AG

13.8.1. Company Details

13.8.2. Company Overview

13.8.3. Product Offerings

13.8.4. Key Developments

13.8.5. Financial Analysis

13.8.6. SWOT Analysis

13.8.7. Business Strategies


 

13.9. Advanced Medical Isotope Corporation

13.9.1. Company Details

13.9.2. Company Overview

13.9.3. Product Offerings

13.9.4. Key Developments

13.9.5. Financial Analysis

13.9.6. SWOT Analysis

13.9.7. Business Strategies

13.10. Alliance Medical Limited

13.10.1.  Company Details

13.10.2.  Company Overview

13.10.3.  Product Offerings

13.10.4.  Key Developments

13.10.5.  Financial Analysis

13.10.6.  SWOT Analysis

13.10.7.  Business Strategies

13.11. Alseres Pharmaceuticals, Inc.

13.11.1.  Company Details

13.11.2.  Company Overview

13.11.3.  Product Offerings

13.11.4.  Key Developments

13.11.5.  Financial Analysis

13.11.6.  SWOT Analysis

13.11.7.  Business Strategies

13.12. Avid Radiopharmaceuticals, Inc.

13.12.1.  Company Details

13.12.2.  Company Overview

13.12.3.  Product Offerings

13.12.4.  Key Developments

13.12.5.  Financial Analysis

13.12.6.  SWOT Analysis

13.12.7.  Business Strategies

13.13. Actinium Pharmaceuticals, Inc.

13.13.1.  Company Details

13.13.2.  Company Overview

13.13.3.  Product Offerings

13.13.4.  Key Developments

13.13.5.  Financial Analysis

13.13.6.  SWOT Analysis

13.13.7.  Business Strategies

13.14. Immunomedics, Inc.

13.14.1.  Company Details

13.14.2.  Company Overview

13.14.3.  Product Offerings

13.14.4.  Key Developments

13.14.5.  Financial Analysis

13.14.6.  SWOT Analysis

13.14.7.  Business Strategies

13.15. Jubilant Pharma LLC

13.15.1.  Company Details

13.15.2.  Company Overview

13.15.3.  Product Offerings

13.15.4.  Key Developments

13.15.5.  Financial Analysis

13.15.6.  SWOT Analysis

13.15.7.  Business Strategies

13.16. Mallinckrodt Pharmaceuticals

13.16.1.  Company Details

13.16.2.  Company Overview

13.16.3.  Product Offerings

13.16.4.  Key Developments

13.16.5.  Financial Analysis

13.16.6.  SWOT Analysis

13.16.7.  Business Strategies

13.17. Medi-Radiopharma Co., Ltd.

13.17.1.  Company Details

13.17.2.  Company Overview

13.17.3.  Product Offerings

13.17.4.  Key Developments

13.17.5.  Financial Analysis

13.17.6.  SWOT Analysis

13.17.7.  Business Strategies

13.18. Nordion (Canada) Inc.

13.18.1.  Company Details

13.18.2.  Company Overview

13.18.3.  Product Offerings

13.18.4.  Key Developments

13.18.5.  Financial Analysis

13.18.6.  SWOT Analysis

13.18.7.  Business Strategies

13.19. Peregrine Pharmaceuticals, Inc.

13.19.1.  Company Details

13.19.2.  Company Overview

13.19.3.  Product Offerings

13.19.4.  Key Developments

13.19.5.  Financial Analysis

13.19.6.  SWOT Analysis

13.19.7.  Business Strategies

13.20. Positron Corporation

13.20.1.  Company Details

13.20.2.  Company Overview

13.20.3.  Product Offerings

13.20.4.  Key Developments

13.20.5.  Financial Analysis

13.20.6.  SWOT Analysis

13.20.7.  Business Strategies

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

At Absolute Markets Insights, we use both top-down and bottom-up approach for calculating the market estimates and market forecast data. We allocate year-on-year growth rate from 2018 to 2026 and reach to the calculations for the global CAGR. Basically for estimation of the products and applications, usually we follow bottom-up approach, where we track the trends in different regions and their countries. We track down the growth factors, restraints, rules & regulations and opportunities for each country  and its region and finally calculate the global numbers. We first track the growth for the U.S. and Rest of North America. With these factors we can estimate the growth and trend for North America, similar approach would be taken for Europe, Asia Pacific, Latin America and Middle East & Africa. Finally, through our home grown model we reach to estimation and forecasting of the global numbers.   

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends. 

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

 

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 204

    Backtrace:

    File: /home/absolute/public_html/application/views/pages/reportpage.php
    Line: 204
    Function: _error_handler

    File: /home/absolute/public_html/application/controllers/Report.php
    Line: 153
    Function: view

    File: /home/absolute/public_html/index.php
    Line: 315
    Function: require_once